Oral GLP-1s: two approved weight-loss pills, and no oral tirzepatide

What this comes down to

• Two oral GLP-1s are FDA-approved for weight management: the WEGOVY tablet (oral semaglutide, approved December 22, 2025) and FOUNDAYO (orforglipron, approved April 1, 2026). RYBELSUS, also oral semaglutide, is approved for type 2 diabetes.
• The semaglutide tablets come with a dosing ritual: an empty stomach, at most four ounces of water, and a 30-minute wait before food, drink or any other oral medication. Foundayo's label says once daily, with or without food.
• Every approved tirzepatide product — MOUNJARO, ZEPBOUND and their pens — is an injection. There is no approved oral tirzepatide to be a version of.
• Sixteen of the 387 sellers we have read price an oral, sublingual or dissolving tirzepatide, from $159 a month — for a route of administration no approved product uses.
• Our September 2026 PubMed search found no trial-tagged reports of oral or sublingual tirzepatide. The identical filter returns 51 for oral semaglutide, so the filter finds trials in this field when there are any.

Which GLP-1 pills are FDA-approved?

Semaglutide is a peptide, and peptides are destroyed by the gut. The approved tablet gets around that with an absorption enhancer and a set of instructions that are part of the product rather than advice around it. The label tells the patient to take it on an empty stomach in the morning with water, up to four ounces, to swallow it whole without splitting, crushing, chewing or dissolving it, and to wait at least 30 minutes before eating, drinking anything else, or taking any other oral medication^[1]. Those are not comfort tips. They are the conditions under which the drug was measured.

There are two approved oral semaglutide products and they are indicated for different things. RYBELSUS is indicated for glycemic control in adults with type 2 diabetes and for cardiovascular risk reduction in that population^[2]. The WEGOVY tablet is indicated for cardiovascular risk reduction in adults with established cardiovascular disease and either obesity or overweight, and to reduce excess body weight and maintain the reduction long term^[1]. The WEGOVY tablet's own approval is recorded under NDA 218316, dated December 22, 2025^[6]. A weight-loss prescription written against the diabetes product is an off-label prescription, which is legal and is also not the same thing as an approved use — the brand-versus-compounded rules set out why that distinction keeps mattering.

The second approved pill is a different molecule. FOUNDAYO is orforglipron, a small-molecule GLP-1 receptor agonist from Eli Lilly, approved by the FDA on April 1, 2026 under NDA 220934^[4]. Its label indicates it, alongside a reduced-calorie diet and more physical activity, to reduce excess body weight and keep it off in adults with obesity, or with overweight and at least one weight-related condition. It is taken once daily, with or without food, starting at 0.8 mg and stepping up at least 30 days apart to 2.5 mg and then 5.5 mg, with higher steps of 9 mg, 14.5 mg and 17.2 mg if needed^[5]. Because it is a small molecule rather than a peptide, it survives the gut without the empty-stomach routine the semaglutide tablets need. Three of the sellers we review already price it by dose, from $113.85 a month: NowPatient, LillyDirect, and ZipHealth.

Is there an oral tirzepatide?

Asked for every brand name whose generic ingredient is tirzepatide, the openFDA label API returns six spellings, and every one of them is an injection: MOUNJARO, Mounjaro, Mounjaro KwikPen, ZEPBOUND, Zepbound and Zepbound KwikPen^[3]. Asked the same question about semaglutide it returns OZEMPIC, Ozempic, RYBELSUS and WEGOVY, two of which are tablets.

The trial search behind that zero. A PubMed search finds 0 results; the same search for oral semaglutide finds 51.

That is worth stating plainly, because the marketing does not. A compounded tirzepatide troche is not a cheaper version of an approved pill. It is a dosage form that has never been through a trial^[7], of a molecule whose approved products are all injections, and the argument for it is the manufacturing argument rather than the evidence one. The drug that was built to be a tablet is a different molecule entirely — orforglipron, a small one, which is why it survives the gut — and it is now approved as FOUNDAYO. The molecules still in the pipeline are a separate story. What third-party testing proves is the article about that argument.

What do telehealth sellers charge for GLP-1 pills?

Across the 387 sellers we review, 43 publish 71 priced semaglutide or tirzepatide lines for something you swallow or dissolve, from $99 to $2717 a month. Sixteen of those lines are the approved brand tablet, sold by ten sellers including NowPatient, LifeMD, NovoCare Pharmacy and seven more. The rest are compounded, and the difference between the two is not visible in the price. Our price method explains how each figure is read, and the calculator is where a medication price and a membership fee stop being the same number.

Oral, sublingual and dissolving semaglutide and tirzepatide lines, cheapest first

• Ask whether the product is the approved tablet or a compounded one. The answer changes what evidence exists for the thing in your hand, and it is rarely on the product page.
• Ask which pharmacy compounds it, and whether that pharmacy is a state-licensed 503A or an FDA-registered outsourcing facility. Only the second is subject to current good manufacturing practice requirements^[8]; how to check either one is a short and mostly public exercise.
• Ask what dose you are getting in milligrams, not in tablets. Milligrams, milliliters and units is where that arithmetic goes wrong most often.
• Ask what month two costs. An introductory oral price and a maintenance oral price are frequently different numbers on the same page.

Questions people actually ask